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Over the past 14 years, five preventative HIV vaccine trials have been conducted in a randomized, 
double-blinded and placebo-controlled manner. One of these trials (RV144, also known as the Thai 
trial), which evaluated a prime-boost vaccine regimen, provided convincing evidence of modest 
vaccine efficacy (VE). In addition, several innovative HIV vaccine products are now becoming 
available for testing and may be combined into novel prime-boost combinations. Trials with these 
new products need improved methods for evaluating clinical endpoints if they are to be as 
informative as possible and bring us closer to achieving highly effective HIV vaccines. 
These recent advancements have generated a great deal of motivation for a new round of phase IIb 
and III trials using combination prime-boost HIV vaccines (Gilbert et al., 2011). The need to optimize 
the design of such trials and upgrade the statistical methods for evaluating their outcomes is driven 
by several factors, including: the huge toll that the HIV pandemic continues to take on human lives 
and well-being; the many challenges to designing effective HIV vaccines, which arise from both the 
complexities of the human immune system and the high mutability of HIV; and the large cost and 
lengthy duration of the requisite vaccine trials. 
Ideally, immune biomarkers can be used as endpoints of successful immunization long before viral 
loads or survivorship measurements need to be made. Biomarkers associated with VE, such as 
serum titers of IgG antibodies that bind to V1V2-scaffolded Env proteins (in the case of HIV 
vaccines), may serve as 'principal surrogate endpoints' in vaccine trials (Gilbert and Hudgens, 2008). 
Good surrogates of VE can help shorten vaccine trials, reveal candidate vaccine effects of 
importance and guide further vaccine development efforts (Plotkin, 2010). However, because 
estimates of VE based on principal surrogate endpoints are conditional on an individual's potential 
biomarker levels, given vaccine or placebo, such estimates are generally what statistical 
epidemiologists call 'non-identifiable' in standard vaccine trials. 
To address this limitation, Follmann (2006) developed a two-phase trial design including closeout 
placebo vaccination (CPV) of individuals in the trial's control arm, which is not performed in a 
traditional vaccine trial. Under certain assumptions, biomarkers measured after CPV theoretically 
can be treated as baseline covariates that should allow nonparametric estimation of disease risks in 
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both the vaccine and placebo groups. Yet, very little research has been done to determine the best 
methods under the CPV design for sampling immune biomarkers, evaluating their surrogate effects 
and estimating different statistical parameters describing VE conditional potential biomarker values. 
These deficits were largely remedied in a paper recently published by Drs. Ying Huang and Peter 
Gilbert (Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center) and Dr. 
Julian Wolfson (Division of Biostatistics, University of Minnesota School of Public Health). The 
researchers' specific motivation for this study was to gear up the statistical machinery that will soon 
be used to analyze a phase IIb HIV vaccine trial (described in Gilbert et al., 2011), which will be 
launched in South Africa. This forthcoming trial will utilize the two-phase CPV design for surrogate 
marker evaluation. 
Thus, Huang et al. investigated the estimation of VE as a function of potential biomarker value (i.e., 
the 'vaccine efficacy curve') in a two-arm randomization trial incorporating the innovative CPV 
design. They did so both analytically and via simulations, quantitatively exploring the effects of many 
model assumptions. Because the cost of measuring immune biomarkers is such a significant issue 
in large vaccine trials, the authors also investigated how different allocations of uninfected 'controls' 
between vaccine and placebo arms affected the efficiency of estimating different parameters of 
interest (see figure). 
Based on their mathematical treatment, Huang et al. propose a brand new pseudo-score type 
estimator for VE that is appropriate for the augmented CPV design. Their new estimator avoids the 
inflated estimation error for VE that arises from incorporating closeout vaccination data into prior 
estimation procedures. Importantly, the authors also derive an analytic variance estimator for VE 
under the CPV design. This was not possible using the prior estimated-likelihood-based methods 
that relied solely on bootstrap resampling. 
According to Dr. Huang, the research team's new approach "provides an optimal sampling design for 
measuring immune responses from trial participants, to provide the most powerful and efficient 
assessment of immune correlates of protection." Their new approach is now the state-of-the-art for 
HIV vaccine trial analysis. The parameter space explored by Huang et al. suggests that, for the 
upcoming phase IIb licensure trial in South Africa, a design that samples slightly more uninfected 
vaccinees than placebo recipients for immune biomarker measurement may be the best path 
to predicting the new vaccine regimen's overall effect on reducing HIV transmission. 
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Figure provided by the authors 
Variation in the asymptotic efficiencies of estimating various statistical 
parameters in the risk model [describing vaccine efficacy (VE) under 
the two-phase, closeout placebo vaccination (CPV) design] as a 
function of study participant allocation during the trial's second phase. A 
set of candidate surrogate biomarkers (S) is measured for: all infected 
cases in the vaccine arm; a portion of uninfected 'controls' in vaccine 
arm; and a portion of uninfected 'controls' in the placebo arm (i.e., the 
CPV component). Study cost increases (roughly linearly) with the total 
number of participants for which S is measured. The plot on the left 
represents a trial with a total cost of 5 'unit' dollars needed to measure 
the immune biomarkers, while the plot on the right represents a trial 
costing twice as much. Designs with larger allocations of controls to the 
placebo arm (i.e., low values along the x-axis) are better for estimating 
the risk model's intercept and the main correlates effect. In contrast, 
designs with a greater allocation of controls to the vaccine arm are 
more efficient at estimating the main variance effect, the interaction 
term, the average vaccine efficacy as a function of the potential 
biomarker value given assignment to the vaccine arm (AveVE) and the 
predicted overall efficacy of the refined vaccine as a function of the 
location shift in immune response for the refined vaccine versus original 
vaccine [VE(90%)]. See original manuscript for a complete 
mathematical description of the risk model and its assumptions. 
 
